MARD wars. More craziness in the world of CGM marketing from ATTD
A long time ago in a galaxy far, far away…. The CE mark was created. But what is it? The definition according the the EU […]
Blog Posts
It’s ATTD again, and here’s another CGM accuracy study…
As seems to have become the norm in the preamble to the Advanced Technologies and Treatments in Diabetes conference, another accuracy study was released in […]
Holidays. Even from T1D?
The holiday For the past two weeks, I’ve been on a bit of a holiday of a lifetime, taking in the Big 5 (elephant, rhino, […]
CGM: Is “More” always better? Abbott’s Libres. More Data – part 2
In the first part of these two sections dedicated to Libre’s minute by minute data, we looked at how the data presented and what that […]
CGM: Is “More” always better? Abbott’s Libres. More Data – part 1
Abbot – More data In the first part of this series, we looked at Dexcom, it’s claims of greater accuracy, and what benefit that provided. […]
CGM: Is “More” always better? Dexcom’s G7. More Accurate
As we discussed in the first article in this series, there’s a lot of marketing about having More with your CGM, whether that’s accuracy or […]
CGM: Is “More” always better?
Over the past few years we’ve seen a number of the larger CGM manufacturers allowing us to infer that their newer products are better because […]
Location, location, location. Does cannula site affect AID performance?
Rotate your injection or infusion sites. That’s a key message that anyone living with type 1 is delivered very early in their life with the […]
GLP1-RAs and Type 1 Diabetes: A retrospective study of incretin-based therapy use with Open Source AID.
So far in this series we’ve looked at why incretin therapy might be a useful adjunct to traditional type 1 treatment, and also how the […]
GLP1-RAs in Type 1 Diabetes: Dosing and Pharmacokinetics
As we discussed in the previous article, people are starting to use incretins as an adjunct therapy in the treatment of type 1 diabetes. All […]